In Vivo Models and In Vitro Assays for the Assessment of Pertussis Toxin Activity
Marieke Hoonakker,
Naturally circulating pertactin-deficient Bordetella pertussis strains induce distinct gene expression and inflammatory signatures in human dendritic cells
Michiel M Kroes, Alberto Miranda-Bedate, Elise S Hovingh, Ronald Jacobi, Corrie Schot, Elder Pupo, René H M Raeven, Arno A J van der Ark, Jos P M van Putten, Jelle de Wit, Rob Mariman, Elena Pinelli
Novel mumps virus epitopes reveal robust cytotoxic T cell responses after natural infection
Patricia Kaaijk, Maarten E. Emmelot, Hugo D. Meiring, Cécile A. C. M. van Els, Jelle de Wit
Genetic Analysis Reveals Differences in CD8+ T Cell Epitope Regions That May Impact Cross-Reactivity of Vaccine-Induced T Cells against Wild-Type Mumps Viruses
Patricia Kaaijk, Maarten E. Emmelot, Jeroen Kerkhof, Cécile A.C.M. van Els, Hugo D. Meiring, Jelle de Wit, Rogier Bodewes
Proteomic analysis of chicken bone marrow-derived dendritic cells in response to an inactivated IBV + NDV poultry vaccine
Robin H G A van den Biggelaar , Larissa van der Maas, Hugo D Meiring, Jeroen L A Pennings, Willem van Eden, Victor P M G Rutten, Christine A Jansen
Common Reference-Based Tandem Mass Tag Multiplexing for the Relative Quantification of Peptides: Design and Application to Degradome Analysis of Diphtheria Toxoid
Thomas J M Michiels, Madelief A van Veen, Hugo D Meiring, Wim Jiskoot, Gideon F A Kersten, Bernard Metz
Vaccination with meningococcal outer membrane vesicles carrying Borrelia OspA protects against experimental Lyme borreliosis
M J Klouwens, M L M Salverda, J J Trentelman, J I Ersoz, A Wagemakers, M J H Gerritzen, P A van der Ley, J W Hovius
Describing the pre-clinical data of the candidate Lyme vaccine based on Intravacc’s OMV platform, this study shows that OMV’s expressing Borrelia (lipo)proteins is a promising vaccine concept that might lead to protecting humans against Lyme disease. Currently, no vaccine against Lyme disease, the fastest growing and most common tick-borne illness in North America and Europe, is available for humans. Antibiotics are the primary treatment and are usually successful, but only when given in time. A vaccine would limit the use of antibiotics and the potential rise of antibiotic resistance. For more information, see also our press release
Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study
Dani Cohen , Jacob Atsmon, Cécile Artaud, Shiri Meron-Sudai, Marie-Lise Gougeon, Anya Bialik, Sophy Goren, Valeria Asato, Ortal Ariel-Cohen, Arava Reizis, Alexandra Dorman, Carla W G Hoitink, Janny Westdijk, Shai Ashkenazi, Philippe Sansonetti, Laurence A Mulard, Armelle Phalipon
The results of a clinical study with an experimental vaccine against Shigella, intestinal bacteria that cause severe diarrhea and dysentery. The paper was authored by a team of researchers and clinicians at Tel Aviv University, Tel Aviv Sourasky Medical Center, Institut Pasteur, Ariel University and Intravacc. The clinical study in healthy adults shows that the vaccine is well tolerated and immunogenic. Intravacc developed a production process for this conjugate vaccine, manufactured the GMP batch and did stability testing and batch release. For more information, see also our press release
The First-in-Human Synthetic Glycan-Based Conjugate Vaccine Candidate against Shigella
Robert M F van der Put, Carolien Smitsman, Alex de Haan, Martin Hamzink, Hans Timmermans, Joost Uittenbogaard, Janny Westdijk, Michiel Stork, Olga Ophorst, Françoise Thouron, Catherine Guerreiro, Philippe J Sansonetti Armelle Phalipon, Laurence A Mulard
Degradomics-Based Analysis of Tetanus Toxoids as a Quality Control Assay
Thomas J. M. Michiels, Wichard Tilstra, Martin R J Hamzink, Justin W de Ridder, Maarten Danial, Hugo D Meiring, Gideon F A Kersten, Wim Jiskoot, Bernard Metz
